Versant Venture Capital VI Amends Tempest Therapeutics Stake

TL;DR

Versant Venture Capital VI filed an amendment on 8/12, changing their stake in Tempest Therapeutics. Details TBD.

AI Summary

Versant Venture Capital VI, L.P. filed an amendment to its Schedule 13D on August 12, 2024, regarding its beneficial ownership of Tempest Therapeutics, Inc. The filing indicates a change in the reporting person's holdings, though specific new dollar amounts or percentages are not detailed in this excerpt. The filing is an amendment, suggesting a modification to previously disclosed information about Versant's stake in Tempest Therapeutics.

Why It Matters

This amendment signals a potential shift in the investment strategy or holdings of a significant venture capital firm in a publicly traded biotech company, which could influence market perception and stock movement.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings can indicate significant changes in a major shareholder's position, potentially leading to volatility.

Key Players & Entities

• Versant Venture Capital VI, L.P. (company) — Reporting Person
• Tempest Therapeutics, Inc. (company) — Subject Company
• 20240812 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $1.3501 — t a weighted average price per share of $1.3501 for aggregate proceeds of approximately
• $540,040 — for aggregate proceeds of approximately $540,040. On August 12, 2024, Versant VI sold
• $1.1005 — t a weighted average price per share of $1.1005 for aggregate proceeds of approximately
• $426,993 — for aggregate proceeds of approximately $426,993. SIGNATURE After reasonable inquiry

Filing Documents

• d879964dsc13da.htm (SC 13D/A) — 157KB
• 0001193125-24-199144.txt ( ) — 159KB

From the Filing

SC 13D/A 1 d879964dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Tempest Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87978U108 (CUSIP Number) Versant Venture Capital VI, L.P. Max Eisenberg One Sansome Street, Suite 1650 San Francisco, CA 94104 415-801-8100 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 8, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 87978U108 13D 1. Name of Reporting Persons Versant Venture Capital VI, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) (1) 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 209,941 shares of Common Stock (2) 8. Shared Voting Power 0 9. Sole Dispositive Power 209,941 shares of Common Stock (2) 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 209,941 shares of Common Stock (2) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row 11 0.8% (3) 14. Type of Reporting Person (See Instructions) PN (1) This Schedule 13D is filed by Versant Venture Capital IV, L.P. (Versant IV), Versant Side Fund IV, L.P. (Side Fund IV), Versant Ventures IV, LLC (LLC IV), Versant Venture Capital VI, L.P. (Versant VI), Versant Ventures VI GP, L.P. (GP VI), Versant Ventures VI GP-GP, LLC (LLC VI), Versant Vantage II, L.P. (Vantage II LP), Versant Vantage II GP, L.P. (Vantage II GP), Versant Vantage II GP-GP, LLC (Vantage II LLC and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the Reporting Persons). LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D. (2) These shares are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. (3) Based on 25,207,792 shares of the Issuers Common Stock outstanding as of August 5, 2024, as set forth in the Issuers quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the United States Securities and Exchange Commission (the Commission) on August 8, 2024 (the Form 10-Q). CUSIP No. 87978U108 13D 1. Name of Reporting Persons Versant Ventures VI GP, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) (1) 3. SEC Use Only 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 209,941 shares of Common Stock (2) 9. Sole Dispositive Po

View Full Filing

View this SC 13D/A filing on SEC EDGAR